139.34
Schlusskurs vom Vortag:
$144.88
Offen:
$140.65
24-Stunden-Volumen:
443.63K
Relative Volume:
0.76
Marktkapitalisierung:
$8.13B
Einnahmen:
$633.51M
Nettoeinkommen (Verlust:
$-8.10M
KGV:
-449.48
EPS:
-0.31
Netto-Cashflow:
$131.26M
1W Leistung:
-2.18%
1M Leistung:
-14.34%
6M Leistung:
-2.54%
1J Leistung:
-29.17%
Repligen Corp Stock (RGEN) Company Profile
Firmenname
Repligen Corp
Sektor
Telefon
(781) 449-9560
Adresse
41 SEYON STREET, WALTHAM, MA
Vergleichen Sie RGEN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RGEN
Repligen Corp
|
139.34 | 8.13B | 633.51M | -8.10M | 131.26M | -0.31 |
![]()
ISRG
Intuitive Surgical Inc
|
491.81 | 176.29B | 8.35B | 2.32B | 1.30B | 6.41 |
![]()
BDX
Becton Dickinson Co
|
231.85 | 66.57B | 20.64B | 1.73B | 2.94B | 6.02 |
![]()
ALC
Alcon Inc
|
91.37 | 45.19B | 9.91B | 1.02B | 665.00M | 2.05 |
![]()
RMD
Resmed Inc
|
221.11 | 32.48B | 4.93B | 1.25B | 1.38B | 8.47 |
![]()
BAX
Baxter International Inc
|
33.44 | 17.07B | 17.28B | 108.00M | 391.00M | 0.20 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-18 | Eingeleitet | Evercore ISI | In-line |
2025-02-10 | Eingeleitet | TD Cowen | Buy |
2024-12-17 | Eingeleitet | Canaccord Genuity | Hold |
2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
2024-06-26 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-06-18 | Eingeleitet | Guggenheim | Neutral |
2023-12-04 | Herabstufung | The Benchmark Company | Buy → Hold |
2023-07-20 | Eingeleitet | Wells Fargo | Overweight |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-03-28 | Eingeleitet | The Benchmark Company | Buy |
2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2022-07-20 | Eingeleitet | UBS | Buy |
2021-10-14 | Eingeleitet | Exane BNP Paribas | Outperform |
2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
2020-05-07 | Bestätigt | H.C. Wainwright | Buy |
2020-03-23 | Bestätigt | H.C. Wainwright | Buy |
2019-11-15 | Eingeleitet | Stifel | Buy |
2019-11-01 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
2019-10-15 | Eingeleitet | SVB Leerink | Outperform |
2019-08-28 | Bestätigt | First Analysis Sec | Outperform |
2019-08-23 | Fortgesetzt | Stephens | Overweight |
2019-07-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2018-12-17 | Hochstufung | CL King | Neutral → Buy |
2018-11-12 | Herabstufung | CL King | Buy → Neutral |
2018-09-26 | Eingeleitet | H.C. Wainwright | Neutral |
2017-12-08 | Eingeleitet | Citigroup | Buy |
2017-12-05 | Eingeleitet | JP Morgan | Overweight |
2017-11-13 | Eingeleitet | CL King | Buy |
2017-10-02 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
2017-07-21 | Eingeleitet | William Blair | Outperform |
2017-02-13 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Repligen Corp Aktie (RGEN) Neueste Nachrichten
PNC Financial Services Group Inc. Sells 262 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corp director Hunt Anthony sells $4.08 million in stock By Investing.com - Investing.com South Africa
Repligen Corp director Hunt Anthony sells $4.08 million in stock - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth and valuation challenges - Investing.com
Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Evercore ISI - Defense World
Repligen Co. (NASDAQ:RGEN) Shares Sold by Victory Capital Management Inc. - Defense World
Repligen director Pax Margaret acquires $37,672 in common stock By Investing.com - Investing.com Australia
REPLIGEN Director Margaret Pax Acquires 250 Shares - TradingView
Evercore ISI sets Repligen stock In Line with $155 price target - Investing.com
Demystifying Repligen: Insights From 6 Analyst Reviews - Benzinga
Repligen initiated with an In Line at Evercore ISI - TipRanks
Repligen Corp (RGEN) Shares Up 5.72% on Mar 17 - GuruFocus.com
Repligen Corp (RGEN) Shares Up 5.72% on Mar 15 - GuruFocus.com
REPLIGEN CORP SEC 10-K Report - TradingView
William Blair Brokers Reduce Earnings Estimates for Repligen - Defense World
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack - The Globe and Mail
Oppenheimer & Co. Inc. Purchases New Shares in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corporation’s Acquisition of Bioprocessing PAT Device Portfolio from 908 Devices - Global Legal Chronicle
US Bancorp DE Raises Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen buying 908 Devices’ Bioprocess Analytics portfolio - BioWorld Online
Sanctuary Advisors LLC Sells 268 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World
Truist Financial Corp Trims Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - AOL
Leerink maintains Repligen stock Outperform rating, $200 target - Investing.com
908 Devices stock jumps on Repligen deal (RGEN:NASDAQ) - Seeking Alpha
Repligen acquires 908 Devices’ desktop bioprocessing tech - Investing.com
Repligen acquires 908 Devices’ desktop bioprocessing tech By Investing.com - Investing.com Canada
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Yahoo Finance
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Armenian Reporter
Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Global Retirement Partners LLC Has $53,000 Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Global Hollow Fiber Filtration Market: A Comprehensive Study - openPR
CIBC Asset Management Inc Acquires 81 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Principal Financial Group Inc. Decreases Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen’s SWOT analysis: bioprocessing leader’s stock poised for growth - Investing.com
Repligen stock holds steady after Benchmark maintains rating - Investing.com
Repligen stock holds steady after Benchmark maintains rating By Investing.com - Investing.com UK
Repligen (NASDAQ:RGEN) Price Target Raised to $200.00 - Defense World
Repligen (NASDAQ:RGEN) Price Target Raised to $205.00 - Armenian Reporter
Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Repligen (NASDAQ:RGEN) Earns Buy Rating from HC Wainwright - Defense World
Repligen (NASDAQ:RGEN) Shares Up 8.1% Following Strong Earnings - Defense World
Repligen Earnings: Encouraging Guidance Supports Attractive Growth Story - Morningstar
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Repligen (RGEN) Beats Q4 Earnings Estimates - MSN
Repligen's Q4 Earnings Beat Estimates, Revenues In Line - Yahoo Finance
The Analyst Verdict: Repligen In The Eyes Of 4 Experts - Benzinga
H.C. Wainwright maintains Buy on Repligen, target at $180 - Investing.com
Repligen Corporation (NASDAQ:RGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Canaccord raises Repligen stock target to $170, maintains Hold - Investing.com
Finanzdaten der Repligen Corp-Aktie (RGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):